Down-regulation of SARS-CoV-2 neutralizing antibodies in vaccinated smokers

Text

As of December 7, 2021, coronavirus disease 2019 (COVID-19) has infected more than 2.6 billion people and caused over 5 million deaths worldwide. Vaccination is an effective approach to help control COVID-19 with 8.17 billion vaccine doses thus far administered¹. However, since the vaccines produce a heterogenous immune response, the risk of breakthrough infection is increased in vaccinated individuals who generate low levels of neutralizing antibodies (NAbs)². It is therefore paramount in the fight against COVID-19 to identify individuals who have a higher risk of breakthrough infection despite being vaccinated.

In this study, we addressed the effect of cigarette smoking on the production of NAbs following COVID-19 vaccination since smoking profoundly suppresses the adaptive immune response to pathogen infection³,⁴. We recruited 164 participants between 20 and 58 years old from Beijing Chaoyang Hospital from December 2020 to March 2021, who were divided into smoking and nonsmoking groups (Table S1 and Supplementary Methods). The participants received two vaccine doses of an inactivated whole-virion SARS-CoV-2 vaccine (Sinovac-CoronaVac) two weeks apart (i.e., “Day 0” and “Day 14”), and their serum was collected longitudinally on days 0, 14, 42, and 90 (Table S2). Since the SARS-CoV-2 Spike (S) protein is required for viral entry, serological antibodies on days 0, 14, and 42 targeting Spike (S) protein and its specific domains, including subunit 1 (S1), receptor binding domain (RBD), and subunit 2 extracellular domain (S2ECD), were detected using a protein array (Supplementary Methods).

Antibody levels to S protein and domains (S1, S2ECD, RBD) were elevated 14 and 42 days after COVID-19 vaccination compared to baseline in both participant groups (i.e., “Day 0”). Moreover, RBD antibodies showed significantly higher expression in the nonsmoking group (n=153) than the smoking (n=11) group on day 42 (p<0.0001, Student’s t-test) (Figure 1A and Figures S1-S4).

• Download figure
• Open in new tab

Figure 1: Smokers have a decreased adaptive immune response following COVID-19 vaccination compared to non-smokers.

(A) Comparison of antibody levels to SARS-CoV-2 S-RBD between nonsmoking and smoking groups using a protein array. (B, C) Comparison of SARS-CoV-2 NAb levels in nonsmokers and smokers using a SARS-CoV-2 D614G pseudovirus neutralization assay represented as a (B) boxplot and (C) line chart. For (B) and (C), the y-axis represents the antibody titer that resulted in 50% pseudovirus neutralization (pNT50).

The SARS-CoV-2 Spike D614G substitution is prevalent, with data showing that it increases SARS-CoV-2 infectivity, competitive fitness, and transmission in primary human cells⁵. Therefore, we measured the levels of NAbs on days 0, 14, 42, and 90 following the first vaccine dose using a SARS-CoV-2 pseudovirus neutralization assay with the D614G substitution (Supplementary Methods). NAbs continually increased after the first and second vaccine dose, peaking on day 42 (Figure 1B and 1C). NAbs titers then significantly decreased until day 90 (Figure 1C).

Compared to nonsmokers, the NAb levels in smokers remained low throughout the period of testing. Notably, the median NAb titers in the smoking group was 1.40-, 1.32-, or 3.00-fold lower than that of nonsmoking group on day 14, 42, or 90, respectively (Figure 1B). No correlation was observed between NAbs and other factors [(i.e., age, sex, body-mass index (BMI)] (Figure S5). Altogether, our results indicate that smoking is a specific risk factor for COVID-19 breakthrough infection following vaccination. Further investigation of smoking and how it affects NAb levels in response to COVID-19 vaccination with a larger patient cohort and other COVID-19 vaccines is warranted.